{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T16:04:54Z","timestamp":1770912294675,"version":"3.50.1"},"reference-count":47,"publisher":"Elsevier","isbn-type":[{"value":"9780323852159","type":"print"}],"license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021]]},"DOI":"10.1016\/b978-0-323-85215-9.00022-2","type":"book-chapter","created":{"date-parts":[[2021,8,6]],"date-time":"2021-08-06T14:11:51Z","timestamp":1628259111000},"page":"545-556","source":"Crossref","is-referenced-by-count":9,"title":["Toxicity of psychedelic drugs"],"prefix":"10.1016","author":[{"given":"Daniela","family":"Calina","sequence":"first","affiliation":[]},{"given":"Felix","family":"Carvalho","sequence":"additional","affiliation":[]},{"given":"Anca","family":"Oana Docea","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/B978-0-323-85215-9.00022-2_bib1","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1021\/acschemneuro.8b00237","article-title":"Psychedelics and personality","volume":"9","author":"Aixal\u00e0","year":"2018","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/B978-0-323-85215-9.00022-2_bib2","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1007\/s00204-015-1513-x","article-title":"The hallucinogenic world of tryptamines: an updated review","volume":"89","author":"Ara\u00fajo","year":"2015","journal-title":"Arch. Toxicol."},{"key":"10.1016\/B978-0-323-85215-9.00022-2_bib3","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1007\/s40262-017-0540-6","article-title":"Pharmacokinetics of escalating doses of oral psilocybin in healthy adults","volume":"56","author":"Brown","year":"2017","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/B978-0-323-85215-9.00022-2_bib4","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1016\/S0140-6736(02)08701-9","article-title":"Mescaline use for 5700 years","volume":"359","author":"Bruhn","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/B978-0-323-85215-9.00022-2_bib5","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1089\/jpm.2017.0684","article-title":"Taking psychedelics seriously","volume":"21","author":"Byock","year":"2018","journal-title":"J. Palliat. Med."},{"key":"10.1016\/B978-0-323-85215-9.00022-2_bib6","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.brainresbull.2016.04.016","article-title":"Neuropharmacology of N,N-dimethyltryptamine","volume":"126","author":"Carbonaro","year":"2016","journal-title":"Brain Res. Bull."},{"key":"10.1016\/B978-0-323-85215-9.00022-2_bib7","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1021\/acschemneuro.8b00215","article-title":"Dark classics in chemical neuroscience: mescaline","volume":"9","author":"Cassels","year":"2018","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/B978-0-323-85215-9.00022-2_bib8","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1080\/02791072.1979.10472093","article-title":"Psilocin, bufotenine and serotonin: historical and biosynthetic observations","volume":"11","author":"Chilton","year":"1979","journal-title":"J. Psychedelic Drugs"},{"key":"10.1016\/B978-0-323-85215-9.00022-2_bib9","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.pnpbp.2012.05.022","article-title":"The recreational tryptamine 5-MeO-DALT (N,N-diallyl-5-methoxytryptamine): a brief review","volume":"39","author":"Corkery","year":"2012","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/B978-0-323-85215-9.00022-2_bib10","doi-asserted-by":"crossref","first-page":"355","DOI":"10.31887\/DCNS.2007.9.4\/macrocq","article-title":"Historical and cultural aspects of man\u2019s relationship with addictive drugs","volume":"9","author":"Crocq","year":"2007","journal-title":"Dialogues Clin. Neurosci."},{"key":"10.1016\/B978-0-323-85215-9.00022-2_bib11","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1007\/s13181-013-0295-x","article-title":"2C or not 2C: phenethylamine designer drug review","volume":"9","author":"Dean","year":"2013","journal-title":"J. Med. Toxicol."},{"key":"10.1016\/B978-0-323-85215-9.00022-2_bib12","doi-asserted-by":"crossref","first-page":"184","DOI":"10.2174\/1874467211666181010154139","article-title":"Pharmacokinetic and pharmacodynamic aspects of peyote and mescaline: clinical and forensic repercussions","volume":"12","author":"Dinis-Oliveira","year":"2019","journal-title":"Curr. Mol. Pharmacol."},{"key":"10.1016\/B978-0-323-85215-9.00022-2_bib13","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.brainresbull.2016.03.002","article-title":"Ayahuasca: pharmacology, neuroscience and therapeutic potential","volume":"126","author":"Dom\u00ednguez-Clav\u00e9","year":"2016","journal-title":"Brain Res. Bull."},{"key":"10.1016\/B978-0-323-85215-9.00022-2_bib14","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1080\/17512433.2018.1511424","article-title":"Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews","volume":"11","author":"dos Santos","year":"2018","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"10.1016\/B978-0-323-85215-9.00022-2_bib15","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.neubiorev.2019.12.001","article-title":"Therapeutic use of serotoninergic hallucinogens: a review of the evidence and of the biological and psychological mechanisms","volume":"108","author":"dos Santos","year":"2020","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/B978-0-323-85215-9.00022-2_bib16","series-title":"European Drug Report 2019: Trends and Developments","year":"2019"},{"key":"10.1016\/B978-0-323-85215-9.00022-2_bib17","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1038\/npp.2009.29","article-title":"5-HT2A and 5-HT2C receptors exert opposing effects on locomotor activity in mice","volume":"34","author":"Halberstadt","year":"2009","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/B978-0-323-85215-9.00022-2_bib18","series-title":"Neuropathology of Drug Addictions and Substance Misuse","article-title":"Chapter 88\u2014Novel drugs of abuse: cannabinoids, stimulants, and hallucinogens","author":"Herrmann","year":"2016"},{"key":"10.1016\/B978-0-323-85215-9.00022-2_bib19","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.pharmthera.2018.11.010","article-title":"Classic psychedelics: an integrative review of epidemiology, therapeutics, mystical experience, and brain network function","volume":"197","author":"Johnson","year":"2019","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/B978-0-323-85215-9.00022-2_bib20","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1080\/00498250802491654","article-title":"In vivo metabolism of \u03b1-methyltryptamine in rats: Identification of urinary metabolites","volume":"38","author":"Kanamori","year":"2008","journal-title":"Xenobiotica"},{"key":"10.1016\/B978-0-323-85215-9.00022-2_bib21","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/dta.319","article-title":"A brief history of \u2018new psychoactive substances\u2019","volume":"3","author":"King","year":"2011","journal-title":"Drug Test Anal."},{"key":"10.1016\/B978-0-323-85215-9.00022-2_bib22","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.biopsych.2012.04.005","article-title":"Psilocybin biases facial recognition, goal-directed behavior, and mood state toward positive relative to negative emotions through different serotonergic subreceptors","volume":"72","author":"Kometer","year":"2012","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/B978-0-323-85215-9.00022-2_bib23","doi-asserted-by":"crossref","first-page":"98","DOI":"10.12688\/f1000research.2-98.v1","article-title":"Over 30 million psychedelic users in the United States","volume":"2","author":"Krebs","year":"2013","journal-title":"F1000Res"},{"key":"10.1016\/B978-0-323-85215-9.00022-2_bib24","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.mehy.2018.03.010","article-title":"Out of the box: a psychedelic model to study the creative mind","volume":"115","author":"Kuypers","year":"2018","journal-title":"Med. Hypotheses"},{"key":"10.1016\/B978-0-323-85215-9.00022-2_bib25","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1177\/0269881119857204","article-title":"Microdosing psychedelics: more questions than answers? An overview and suggestions for future research","volume":"33","author":"Kuypers","year":"2019","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/B978-0-323-85215-9.00022-2_bib26","doi-asserted-by":"crossref","first-page":"663","DOI":"10.2174\/1570159X15666161111112545","article-title":"Recent trends in analytical methods to determine new psychoactive substances in hair","volume":"15","author":"Kyriakou","year":"2017","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/B978-0-323-85215-9.00022-2_bib27","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1080\/03602532.2019.1638931","article-title":"Metabolism of lysergic acid diethylamide (LSD): an update","volume":"51","author":"Lib\u00e2nio Os\u00f3rio Marta","year":"2019","journal-title":"Drug Metab. Rev."},{"key":"10.1016\/B978-0-323-85215-9.00022-2_bib28","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/7854_2017_478","article-title":"Hallucinogens and serotonin 5-HT(2A) receptor-mediated signaling pathways","volume":"36","author":"L\u00f3pez-Gim\u00e9nez","year":"2018","journal-title":"Curr. Top. Behav. Neurosci."},{"key":"10.1016\/B978-0-323-85215-9.00022-2_bib29","first-page":"8","article-title":"Hallucinogen persisting perception disorder: etiology, clinical features, and therapeutic perspectives","author":"Martinotti","year":"2018","journal-title":"Brain Sci."},{"key":"10.1016\/B978-0-323-85215-9.00022-2_bib30","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1080\/02791072.2000.10400456","article-title":"Bufotenine: toward an understanding of possible psychoactive mechanisms","volume":"32","author":"Mcbride","year":"2000","journal-title":"J. Psychoact. Drugs"},{"key":"10.1016\/B978-0-323-85215-9.00022-2_bib31","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1007\/s00204-016-1812-x","article-title":"New psychoactive substances: an overview on recent publications on their toxicodynamics and toxicokinetics","volume":"90","author":"Meyer","year":"2016","journal-title":"Arch. Toxicol."},{"key":"10.1016\/B978-0-323-85215-9.00022-2_bib32","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.pharmthera.2003.11.002","article-title":"Hallucinogens","volume":"101","author":"Nichols","year":"2004","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/B978-0-323-85215-9.00022-2_bib33","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1124\/pr.115.011478","article-title":"Psychedelics","volume":"68","author":"Nichols","year":"2016","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/B978-0-323-85215-9.00022-2_bib34","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1021\/acschemneuro.8b00043","article-title":"Dark classics in chemical neuroscience: lysergic acid diethylamide (LSD)","volume":"9","author":"Nichols","year":"2018","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/B978-0-323-85215-9.00022-2_bib35","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/j.1749-6632.1957.tb40738.x","article-title":"A review of the clinical effects of psychotomimetic agents","volume":"66","author":"Osmond","year":"1957","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/B978-0-323-85215-9.00022-2_bib36","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/jat\/bkv073","article-title":"Analysis of 25I-NBOMe, 25B-NBOMe, 25C-NBOMe and other dimethoxyphenyl-N-[(2-Methoxyphenyl) methyl]ethanamine derivatives on blotter paper","volume":"39","author":"Poklis","year":"2015","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/B978-0-323-85215-9.00022-2_bib37","doi-asserted-by":"crossref","first-page":"659","DOI":"10.2174\/138920010794233495","article-title":"Psychedelic 5-methoxy-N,N-dimethyltryptamine: metabolism, pharmacokinetics, drug interactions, and pharmacological actions","volume":"11","author":"Shen","year":"2010","journal-title":"Curr. Drug Metabolism"},{"key":"10.1016\/B978-0-323-85215-9.00022-2_bib38","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1159\/000085649","article-title":"Binding properties of dipropyltryptamine at the human 5-HT1a receptor","volume":"74","author":"Thiagaraj","year":"2005","journal-title":"Pharmacology"},{"key":"10.1016\/B978-0-323-85215-9.00022-2_bib39","doi-asserted-by":"crossref","first-page":"26","DOI":"10.2174\/1570159X13666141210222409","article-title":"Recreational use, analysis and toxicity of tryptamines","volume":"13","author":"Tittarelli","year":"2015","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/B978-0-323-85215-9.00022-2_bib40","doi-asserted-by":"crossref","unstructured":"Tyl\u0161, F., Palenicek, T., Horacek, J., 2016. Neurobiology of the Effects of Psilocybin in Relation to Its Potential Therapeutic Targets.","DOI":"10.1016\/B978-0-12-800212-4.00073-X"},{"key":"10.1016\/B978-0-323-85215-9.00022-2_bib41","doi-asserted-by":"crossref","first-page":"265","DOI":"10.31887\/DCNS.2001.3.4\/fxvollenweider","article-title":"Brain mechanisms of hallucinogens and entactogens","volume":"3","author":"Vollenweider","year":"2001","journal-title":"Dialogues Clin. Neurosci."},{"key":"10.1016\/B978-0-323-85215-9.00022-2_bib42","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.1097\/00001756-199812010-00024","article-title":"Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action","volume":"9","author":"Vollenweider","year":"1998","journal-title":"Neuroreport"},{"key":"10.1016\/B978-0-323-85215-9.00022-2_bib43","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13722-015-0024-7","article-title":"Designer drugs 2015: assessment and management","volume":"10","author":"Weaver","year":"2015","journal-title":"Addict. Sci. Clin. Pract."},{"key":"10.1016\/B978-0-323-85215-9.00022-2_bib44","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1007\/s13181-012-0264-9","article-title":"The Toxicology Investigators Consortium Case Registry\u2013the 2011 experience","volume":"8","author":"Wiegand","year":"2012","journal-title":"J. Med. Toxicol."},{"key":"10.1016\/B978-0-323-85215-9.00022-2_bib45","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1002\/dta.2044","article-title":"25C-NBOMe and 25I-NBOMe metabolite studies in human hepatocytes, in vivo mouse and human urine with high-resolution mass spectrometry","volume":"9","author":"Wohlfarth","year":"2017","journal-title":"Drug Test Anal."},{"key":"10.1016\/B978-0-323-85215-9.00022-2_bib46","series-title":"Addictive Substances and Neurological Disease","article-title":"Chapter 29\u2014Novel psychoactive substances: a new behavioral and mental health threat","author":"Zanda","year":"2017"},{"key":"10.1016\/B978-0-323-85215-9.00022-2_bib47","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3389\/fnins.2020.00078","article-title":"NBOMes-highly potent and toxic alternatives of LSD","volume":"14","author":"Zawilska","year":"2020","journal-title":"Front Neurosci."}],"container-title":["Toxicological Risk Assessment and Multi-System Health Impacts from Exposure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:B9780323852159000222?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:B9780323852159000222?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T17:05:42Z","timestamp":1756141542000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/B9780323852159000222"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"ISBN":["9780323852159"],"references-count":47,"URL":"https:\/\/doi.org\/10.1016\/b978-0-323-85215-9.00022-2","relation":{},"subject":[],"published":{"date-parts":[[2021]]}}}